Summary
Updated Aug 30, 2026
Laura Stoppel is Director of Acumen Pharmaceuticals, Inc. (ABOS). 1 SEC Form 4 filing on record, dated 5 June 2026.
Recent Transactions
1Every recent SEC Form 4 transaction Laura Stoppel has reported, most recent first.
Other Insiders Active in the Same Stocks
Insiders who reported open-market trades in the last 12 months at the companies Laura Stoppel files at. Multiple unrelated insiders buying the same stock within a short window, cluster buying, has historically been one of the strongest Form 4 signals.
- Derek M. Meisner - $105K of ABOS open-market activity in the last 12 months
- Derrell Porter - $75K of ABOS open-market activity in the last 12 months
- Daniel Joseph Oconnell - $22K of ABOS open-market activity in the last 12 months
- Nathan B. Fountain - $14K of ABOS open-market activity in the last 12 months
- Matt Zuga - $8K of ABOS open-market activity in the last 12 months
- Eric Siemers - $6K of ABOS open-market activity in the last 12 months
More Notable Insiders
Other corporate insiders with significant SEC Form 4 track records on InsiderAlpha:
Frequently Asked Questions
Who is Laura Stoppel?
Laura Stoppel is a corporate insider, tracked as Director of Acumen Pharmaceuticals, Inc. (ABOS). InsiderAlpha holds 1 primary Form 4 filing for them, the earliest from 2026, updated as new SEC EDGAR filings are processed.
How many SEC Form 4 filings has Laura Stoppel submitted recently?
1 primary Form 4 filing in the last 90 days, covering 1 company.
Where can I see all of Laura Stoppel's SEC filings?
All Form 4 filings, transaction values, and 10b5-1 plan flags are listed on this page and updated in real time as new SEC EDGAR filings are processed.
Learn More
Follow Laura Stoppel and every insider like them
A free account opens the full scored daily plan and every past day, a watchlist for any ticker, and 3 months of price history on every company page. No card.
Free plan available · Paid plans start with a 7-day free trial
